GHRH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Arrestins block GPCR coupling to G proteins in two ways. First, arrestin binding to the cytoplasmic face of the receptor occludes the binding site for heterotrimeric G-protein, preventing its activation (desensitization). Second, arrestin links the receptor to elements of the internalization machinery, clathrin and clathrin adaptor AP2, which promotes receptor internalization via coated pits and subsequent transport to internal compartments, called endosomes. Subsequently, the receptor could be either directed to degradation compartments (lysosomes) or recycled back to the plasma membrane where it can again signal. The strength of arrestin-receptor interaction plays a role in this choice: tighter complexes tend to increase the probability of receptor degradation (Class B), whereas more transient complexes favor recycling (Class A), although this rule is far from absolute. More recently direct interactions between Gi/o family G proteins and Arrestin were discovered downstream of multiple receptors, regardless of canonical G protein coupling. These recent findings introduce a GPCR signaling mechanism distinct from canonical G protein activation and β-arrestin desensitization in which GPCRs cause the formation of Gαi:β-arrestin signaling complexes.
Catherine E. Costello is the William Fairfield Warren distinguished professor in the department of biochemistry, Cell Biology and Genomics, and the director of the Center for Biomedical Mass Spectrometry at the Boston University School of Medicine. Catherine E. Costello attended the Emmanuel College in Boston for her undergraduate studies in chemistry, and minors in mathematics and physics. She received a Master of Science (1967) and a PhD from Georgetown University (1971). After graduation, she did post-doctoral research with Klaus Biemann at Massachusetts Institute of Technology.
If recovery of usable ruthenium is a goal, an extremely pure technetium target is needed; if small traces of the minor actinides such as americium and curium are present in the target, they are likely to undergo fission and form more fission products which increase the radioactivity of the irradiated target. The formation of ruthenium-106 (half-life 374 days) from the 'fresh fission' is likely to increase the activity of the final ruthenium metal, which will then require a longer cooling time after irradiation before the ruthenium can be used. The actual separation of technetium-99 from spent nuclear fuel is a long process. During fuel reprocessing, it comes out as a component of the highly radioactive waste liquid. After sitting for several years, the radioactivity reduces to a level where extraction of the long-lived isotopes, including technetium-99, becomes feasible. A series of chemical processes yields technetium-99 metal of high purity.
In physics, the first law of thermodynamics is an expression of the conservation of total energy of a system. The increase of the energy of a system is equal to the sum of work done on the system and the heat added to that system:
Sources: en.wikipedia.org
== Management == Management of FM symptoms, to improve quality of life, often uses integrated pharmacological and non-pharmacological approaches. There is no single intervention shown to be effective for all patients. A personalized, multidisciplinary approach to treatment that includes pharmacologic considerations and begins with effective patient education is most beneficial. Self-help can play a role. Several associations have published guidelines for the diagnosis and management of fibromyalgia, including the German Federal Ministry of Health in 2022, Italian guidelines in 2021, the European League Against Rheumatism in 2017, and the Canadian Pain Society in 2012.
In materials science and engineering, there is often interest in understanding the forces or stresses involved in the deformation of a material. For instance, if the material were a simple spring, the answer would be given by Hooke's law, which says that the force experienced by a spring is proportional to the distance displaced from equilibrium. Stresses which can be attributed to the deformation of a material from some rest state are called elastic stresses. In other materials, stresses are present which can be attributed to the deformation rate over time. These are called viscous stresses. For instance, in a fluid such as water the stresses which arise from shearing the fluid do not depend on the distance the fluid has been sheared; rather, they depend on how quickly the shearing occurs. Viscosity is the material property which relates the viscous stresses in a material to the rate of change of a deformation (the strain rate). Although it applies to general flows, it is easy to visualize and define in a simple shearing flow, such as a planar Couette flow. In the Couette flow, a fluid is trapped between two infinitely large plates, one fixed and one in parallel motion at constant speed
Bush's special envoy for human rights in North Korea Steven Waldman (1984), senior advisor to the chairman of the Federal Communications Commission and founder of Beliefnet John Delaney (1985), U.S. congressman for Maryland's 6th congressional district and candidate in the 2020 United States presidential election Julius Genachowski (1985), chairman of the Federal Communications Commission Hector Morales (1985), U.S. ambassador to the Organization of American States 2008–2009 Daniel Lewis Foote (1986), former U.S. ambassador to Zambia Michael Mundaca (1986), former assistant secretary for tax policy in the U.S. Department of the Treasury Sharon Block (1987), acting administrator of the Office of Information and Regulatory Affairs, former member of the National Labor Relations Board and professor at Harvard Law School David M. Friedman (1987), current U.S.
Various types of alcohol were also used in ancient medical practices. One of the first uses was wine mixed with oil was a common remedy in the ancient world to cleanse wounds and assuage their pain as noted in the context of Alcohol in the Bible. The Sumerians used beer as an antiseptic along with the dressing of wounds, using up to 19 different types of beer. Other ancient Mesopotamian cultures, including the Sumerians and Akkadians used wine with sesame infusions, which were "purified and pulverized" before application along with the many beers. A medical prescription from Mesopotamia describes a method for healing wounds:
Commercial motor vehicles such as cars, vans, trucks, specialist vehicles (such as mobile construction machinery), forklifts, and trailers Private vehicles used for work purposes (the 'grey fleet') Aviation machinery such as aircraft (planes and helicopters) Ships Rail cars Non-powered assets such as generators, tanks, gear boxes, dumpsters, shipping containers, trailers, excavators, and other equipment that can't run on its own power. Fleet (vehicle) management can include a range of functions, such as vehicle leasing and financing, vehicle maintenance, licensing and compliance, supply chain management, accident management and subrogation, vehicle telematics (tracking and diagnostics), driver management, speed management, fuel management, health and safety management, and vehicle re-marketing. Fleet Management is a function which allows companies which rely on transportation in business to remove or minimize the risks associated with vehicle investment, improving efficiency, productivity and reducing their overall transportation and staff costs, providing 100% compliance with government legislation (duty of care) and many more. These functions can be dealt with by either an in-house fleet-management department or an outsourced fleet-management provider. The number of light duty vehicles registered in commercial fleets in Europe as of 2016 was 15 million, and 19.5 million in North America. Even with these record numbers of registration, light duty vehicles represent only 62% of all fleet sales.
Sources: en.wikipedia.org
==== I. Lipophilic Drugs ==== Microbubbles can facilitate the local targeting of hydrophobic drugs through the incorporation of these agents into the microbubble lipid shell. This encapsulation technique reduces systemic toxicity, increases drug localization, and improves the solubility of hydrophobic drugs. For increased localization, a targeting ligand can be appended to the exterior of the microbubble. This improves treatment efficacy. One drawback of the lipid-encapsulated microbubble as a drug delivery vehicle is its low payload efficacy. To combat this, an oil shell can be incorporated to the interior of the lipid monolayer to enhance payload efficacy.
The natural history of untreated CTS seems to be gradual worsening of the neuropathy. It is difficult to prove that this is always the case, but the supportive evidence is compelling. Atrophy of the thenar muscles, weakness of palmar abduction, and loss of sensibility (constant numbness as opposed to intermittent paresthesia) are signs of advanced neuropathy. Advanced neuropathy is often permanent. The nerve will try to recover after surgery for more than 2 years, but the recovery may be incomplete. Paresthesia may increase after the release of advanced carpal tunnel syndrome, and people may feel worse than they did before surgery for many months. Troublesome recovery seems related to symptoms of anxiety or depression, and unhelpful thoughts about symptoms (such as worst-case or catastrophic thinking), as well as advanced neuropathy with potentially permanent neuropathy. Recurrence of carpal tunnel syndrome after successful surgery is rare. Caution is warranted in considering additional surgery for people dissatisfied with the result of carpal tunnel release as perceived recurrence may more often be due to renewed awareness of persistent symptoms rather than worsening pathology.
Charge-exchange ionization (also known as charge-transfer ionization) is a gas phase reaction between an ion and an atom or molecule in which the charge of the ion is transferred to the neutral species.
Commission D2: Refrigerated Transport The IIR's Commission D2 on Refrigerated Transport is extremely active. In addition to the IIR's four-yearly congress, Commission D2 participates in the IIR Conference on Sustainability and the Cold Chain, held out of synchronisation with the congress. Every year, Commission D2 CERTE test engineers meet in a European country to discuss refrigerated transport technology and testing issues. This group subsequently advises the United Nations working party on transport of perishable foodstuffs held each year in Geneva. Commission D2 is currently addressing the “Cold Chain for Pharmaceutical Products” and will add this to regular transport discussion and advisory topics. Commission D2 also helps to produce Informatory Notes to assist in areas of technical or regulatory difficulty. The IIR is recognised, for its contributions to refrigerated transport, particularly through the work of its Commission D2. The commission's research addresses food waste reduction and emissions mitigation.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.